• Clinical Insights: April 1, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Zeposia® (ozanimod) Capsules – New Drug Approval – March 26, 2020 – Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Zeposia® (ozanimod) 0.92… Read more »

  • Clinical Insights: March 24, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Isturisa® (osilodrostat) Tablets – New Orphan Drug Approval – March 6, 2020 – The U.S. Food and Drug Administration announced the approval of Isturisa® (osilodrostat)… Read more »

  • Connect with RxStrategies at the 340B Coalition Winter Conference

    The 2020 340B Coalition Winter Conference is near! RxStrategies is a proud Pinnacle Level sponsor of this great event, where attendees will receive the latest actionable intelligence in areas such as 340B implementation and operations, compliance, contract pharmacy, inventory management, and specialty pharmacy. The conference will take place in San Diego, CA, February 10 –… Read more »

  • Happy Holidays!

      Happy Holidays from the RxStrategies team! Wishing you a time filled with fun and joy. Best wishes for the New Year!   Warm Regards, The RxStrategies Team

  • Connect With RxStrategies at the ASHP Midyear Clinical Meeting & Exhibition

    RxStrategies will be an exhibitor at the ASHP Midyear Clinical Meeting & Exhibition in Las Vegas, NV, December 8 – 12. As the world’s largest gathering of pharmacy professionals, ASHP Midyear provides a space for conversation, learning, and networking for all attendees.   Skip Devanny, Rhodie Smith, Jonathan Ghenn and Justin Rolling will be representing… Read more »

  • Connect with RxStrategies at the 2019 Fall Hospital Pharmacy Conference

    RxStrategies will be at the Fall Hospital Pharmacy (HCP) Conference on October 28-30 in Kansas City, MO. Team members Justin Rolling and Rhodie Smith will be networking with peers, attending educational sessions and sharing their expertise in 340B solutions. Learn more about the conference here.   Contact us to connect during the conference and learn… Read more »

  • Let’s Connect: 2019 NWRPCA/CHAMPS Fall Primary Care Conference

    RxStrategies’ Todd Hudnall and Krista Scanlon will attend the 2019 NWRPCA/CHAMPS Fall Primary Care Conference in Seattle. The conference takes place October 5 – 8, and provides education and training, information and resource sharing, coalition building, and program and policy development for like-minded community health professionals and their partners. Learn more about the event here.… Read more »

  • Clinical Insights: September 30, 2019

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Jynneos™ (smallpox and monkeypox vaccine, live, nonreplicating) – New Vaccine Approval – September 24, 2019 – The U.S. Food and Drug Administration announced the approval… Read more »

  • Let’s Connect: APHCA Annual Conference and Expo

    RxStrategies is proud to be a Platinum Presenting Sponsor of Alabama Primary Health Care Association’s (APHCA) Annual Bootcamp, Conference and Expo. The event is the State’s largest annual gathering of community health systems, providers and partners from across the community of care. This year’s annual event, Taking Point, will be held on October 1-3, 2019 at… Read more »

  • Clinical Insights: September 13, 2019

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Ibsrela® (tenapanor) – New Drug Approval – September 12, 2019 – Ardelyx, Inc., announced that the U.S. Food and Drug Administration has approved Ibsrela®… Read more »